|Target||IL4 receptor alpha|
|Mol. mass||146.9 kDa|
Dupilumab is a monoclonal antibody designed for the treatment of atopic diseases. It binds to the alpha subunit of the interleukin-4 receptor (IL-4Rα). Through blockade of IL-4Rα, dupilumab modulates signaling of both the IL-4 and IL-13 pathway, which have been implicated in the pathophysiology of allergic disease.
This drug was developed by Regeneron Pharmaceuticals.
On May 21/2013 mid-stage data was presented at the American Thoracic Society meeting and published in the NEJM demonstrating an 87% reduction in asthma exacerbations in patients with moderate-to-severe allergic asthma.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Dupilumab, American Medical Association.
- Dupilumab in Persistent Asthma with Elevated Eosinophil Levels - Sally Wenzel, M.D., Linda Ford, M.D., David Pearlman, M.D., Sheldon Spector, M.D., Lawrence Sher, M.D., Franck Skobieranda, M.D., Lin Wang, Ph.D., Stephane Kirkesseli, M.D., Ross Rocklin, M.D., Brian Bock, D.O., Jennifer Hamilton, Ph.D., Jeffrey E. Ming, M.D., Ph.D., Allen Radin, M.D., Neil Stahl, Ph.D., George D. Yancopoulos, M.D., Ph.D., Neil Graham, M.D., and Gianluca Pirozzi, M.D., Ph.D., NEJM.
- Regeneron press release March 2, 2013
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|